Background. The 7-valent and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) are highly effective in preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes. Vaccine failure (vaccine-type IPD after age-appropriate immunization) is rare. Little is known about the risk, clinical characteristics, or outcomes of PCV13 compared to PCV7 vaccine failure.
In the United Kingdom, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in September 2006 as a 2 + 1 schedule for all infants at 2, 4, and 12 months alongside a 12-month limited catch-up for <2-year-olds [1] . The program led to a rapid decline in invasive pneumococcal disease (IPD) and, since young children are the main carriers of Streptococcus pneumoniae and PCV7 reduces carriage acquisition [2] , significant reductions in PCV7-type IPD were observed across all age groups, with overall IPD rates falling by 34% [3] . From April 2010, PCV7 was replaced by a 13-valent pneumococcal conjugate vaccine (PCV13) without any catch-up and, by 2013-2014, IPD incidence had fallen by a further 32% because of continued reduction in PCV7-type IPD and a 69% reduction in PCV13-type IPD [4] .
The development of vaccine-serotype IPD in a PCVimmunized child (ie, vaccine failure) is rare [5] . Although a number of studies have described children with PCV7 failure, little is known about PCV13 failure. Because individual pneumococcal serotypes have different propensities for invasiveness and disease, and since vaccine immunogenicity varies for the different serotypes, it is likely that the characteristics of children with PCV13 failure are different to those with PCV7 failure. This study aimed to describe the rate, vaccination status, serotype distribution, clinical characteristics, and outcomes of children aged <5 years with PCV7 and PCV13 failure in England and Wales over an 8-year period.
all laboratory-confirmed IPD cases in children aged <5 years [3] . In brief, hospital laboratories routinely report clinically significant infections to PHE electronically and submit invasive pneumococcal isolates to the national PHE Reference Laboratory for confirmation and serotyping. As part of enhanced national surveillance, general practitioners and hospital pediatricians for <5 year-olds with laboratory-confirmed IPD completed a short questionnaire on vaccination history, known comorbidities at the time of IPD, complications, and outcomes. In the United Kingdom, children are actively called and immunized by their general practitioners, and their vaccinations are documented in their individual electronic records. For this study, all children born since 4 September 2004 (ie, including <2-year-olds eligible for the initial catch-up) with PCV failure diagnosed during 4 September 2006 to 3 September 2014 (ie, 8-year period) were included.
Definitions
IPD was defined as S. pneumoniae cultured from a normally sterile site or pneumococcal DNA detected in cerebrospinal fluid (CSF) or pleural fluid. Meningitis was defined as S. pneumoniae identified (culture/polymerase chain reaction [PCR]) in the CSF or S. pneumoniae cultured from blood with radiological and/or clinical features of meningitis. Lower respiratory tract infection (LRTI) was defined as S. pneumoniae identified in pleural/empyema fluid or in blood with a radiological and/ or clinical diagnosis of pneumonia. Septicemia was defined as S. pneumoniae cultured in blood with no clear focus of infection. Comorbidity was defined as presence of a high-risk condition as defined in the Green Book on Immunisation [6] . For children with >1 IPD episode, only the first episode was included in the primary analysis; subsequent episodes are described separately.
Of the cases eligible for PCV7 only, the vaccine failure group was composed of 3 cohorts aged <5 years at diagnosis: PCV7-type IPD in a child (i) ≥14 days after 2 doses in <12-montholds (PCV7-PCV7); (ii) ≥7 days after a single PCV7 dose in ≥12-month-olds (PCV7 catch-up); or (iii) ≥7 days after 3 PCV7 doses including the 12-month booster (PCV7-PCV7-PCV7). By definition, these cohorts could still be diagnosed even after PCV13 introduction if they only received PCV7, were diagnosed with PCV7-type IPD, and were aged <5 years at diagnosis. The vaccine failure group that was eligible for ≥1 PCV13 dose also included 3 cohorts aged <5 years at diagnosis: IPD caused by the additional PCV13 serotypes (1, 3, 5, 6A, 7F, and 19A) (i) ≥14 days after 2 doses in <12-month-olds (PCV13-PCV13); (ii) ≥7 days after PCV7 in infancy with a 12-month PCV13 booster (PCV13 catch-up); and (iii) ≥7 days after 3 PCV13 doses including the 12-month booster (PCV13-PCV13-PCV13).
Data Analysis
Data were analyzed using Stata software version 11.0 (StataCorp, College Station, Texas) and are mainly descriptive.
The denominator for the vaccine failure rate was calculated by multiplying the number of children aged <5 years who were eligible for a specific vaccine schedule nationally (www.statistics.gov.uk) with the vaccine coverage and the eligible time period for that schedule. Childhood vaccine coverage for both PCV7 and PCV13 has remained consistently high (>90%) over the years (https://www.gov.uk/government/collections/ immunization) [7] . Categorical variables were described as percentages with binomial 95% confidence intervals (CIs) and compared using the χ 2 test or 2-tailed Fisher exact test.
Continuous variables that did not follow a normal distribution were described as median with interquartile range (IQR) and compared using the Mann-Whitney U test. Multivariable logistic regression was used to investigate relationships between variables using the largest group as the baseline and adjusting for age as a continuous variable, sex, and comorbidity status. Data are presented as No. (%) unless otherwise indicated. Proportions of individual serotypes causing IPD in England and Wales during the epidemiological year prior to PCV introduction were compared using the χ 2 test against the proportion of IPD cases caused by the same serotypes in vaccinated children after PCV introduction. After applying the Bonferroni correction for multiple comparisons, P < .007 was considered statistically significant for the PCV7 serotypes and P < .003 for the PCV13 serotypes (highlighted in bold).
Abbreviations: IPD, invasive pneumococcal disease; mo, months; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
2 were in fully immunized children; the others were either in the PCV7-PCV7-PCV13 group (n = 9) or developed IPD after their first birthday (5 of 7 cases diagnosed at 12-14 months of age) following a delay in receiving their 12-month booster. In contrast, 12 of 33 (36%) serotype 3 IPD cases after 12 months of age occurred in fully immunized children, 16 in the PCV7-PCV7-PCV13 group and 5 in those with delayed 12-month booster. PCV7 failure rate after 3 doses was 0.19/100 000 person-years (95% CI, .10-.33) and 0.66/100 000 person-years (95% CI, .44-.95) after 3 PCV13 doses ( Table 1 ). The annual incidence of vaccine failure cases declined with time since PCV7 introduction, but this was less marked after PCV13 introduction (Figure 1 ). The increase in vaccine failure rates from 2010-2011 was due to the inclusion of the additional PCV13 serotypes. Children with PCV13 failure were more likely to have been 
Clinical Presentation
Overall, LRTI (n = 72 [45%]) was the most common clinical presentation (Table 3) 
more likely to cause vaccine failure in healthy children than those with comorbidity ( Figure 3) Abbreviations: LRTI, lower respiratory tract infection; mo, months; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine. a P < .01 (proportions were compared using the χ 2 test between cases eligible for PCV7 only and those eligible for ≥1 PCV13).
Repeat Episodes and Case Fatality
One toddler with congenital hydrocephalus and a ventriculoperitoneal shunt suffered 2 episodes of serotype 6B meningitis, with the first episode occurring 5 months after a PCV7 catch-up dose. A second toddler with congenital deafness developed 2 episodes of serotype 4 meningitis after 3 PCV7 doses, with the first episode occurring 2 weeks after cochlear implantation [2, 8] .
Case fatality rate (CFR) among vaccine failure cases was 4% (n = 6; 95% CI, 1%-8%) ( 
DISCUSSION
In England and Wales, PCV failure was rare, with only 161 children diagnosed in 10 birth cohorts diagnosed over 8 years (<1/100 000 vaccinated person-years). Vaccine failure rates were higher after 2 PCV doses in infancy and lowest after completion of the recommended 3-dose schedule, most likely because of a combination of factors, including higher vaccine effectiveness after 3 doses, lower IPD incidence in older ages, and more time for herd protection effects after PCV introduction. PCV13 failure cases were more likely to be healthy and develop LRTI, whereas those with PCV7 failure were more likely to have comorbidities and develop septicemia. Only a third of PCV13 failure cases had comorbidity, mainly immunosuppression and cardiac abnormality. Recurrent IPD was rare (2 children) and the CFR was low (6 children), both associated with underlying comorbidity. Following 3 infant doses of the Haemophilus influenzae type b (Hib) conjugate vaccine, the vaccine failure rate was 2.2/100 000 UK children over 6 years and 5 months [9] . For the meningococcal group C (MenC) conjugate vaccine, only 53 vaccine failure cases were identified among <18-year-olds during the first 4 years after vaccine introduction [10] . Potential explanations for vaccine failure include the presence of underlying comorbidities and waning antibodies after vaccination, which has been described for both Hib and MenC vaccine failures [9, 10] .
In the United Kingdom, PCV7 introduction rapidly achieved high vaccine coverage, resulting in 98% and 93% lower PCV7-type IPD rates within 4 years in <2-year-olds and 2-to 4-yearolds, respectively [3] . Compared to serotypes causing IPD in the pre-PCV7 period, serotypes 6B and 19F were over-represented among vaccine failure cases. These 2 serotypes had the lower antibody responses after infant immunization [11] , and the lowest serotype-specific vaccine effectiveness after PCV7 introduction (49% and 70%, respectively) [12] . Others have also reported a predominance of these 2 serotypes among PCV7 failure cases, which were responsible for 59% of PCV7 failures in our cohort [13] . Comorbidity prevalence in the published literature, relating almost exclusively to PCV7 failures, ranged between 10% and 36%, which is in keeping with the rates in our cohort [5] , with immunosuppression, mainly malignancy, and cardiac conditions predominating.
After PCV13 introduction, serotype 3 was over-represented among vaccine failures. Low vaccine effectiveness for this serotype has been reported in England and Wales [14] , although some protection was observed in the United States [15] . In infants, serotype 3 elicited the lowest post-primary and post-booster antibody responses of the additional PCV13 serotypes [16] . For this serotype, it is estimated that very higher serum immunoglobulin G (IgG) concentrations (>2.83 µg/mL) are required for protection against disease compared to the internationally accepted threshold of 0.35 µg/mL [14] ; such high concentrations were rarely attained after vaccination [16] . On the other hand, although serotype 19A is immunogenic in infants [16] , vaccine effectiveness against this serotype has been poor (62% after 2 infant doses, and 67% after 3 doses including the 12-month booster). A higher correlate for protection (>1.0 µg/mL) has also been estimated for this serotype [14] .
In our cohort, the clustering of serotype 19A vaccine failure cases around the first birthday may indicate waning immunity after 2 infant priming doses; this was not observed for any other serotype. It is possible that a 3-dose priming schedule might reduce vaccine failure rates before the 12-month booster by inducing higher post-primary immunization antibody concentrations, but this would involve approximately an additional 700 000 doses to prevent around 8 vaccine failure cases, annually.
On the other hand, the vaccine failure cases diagnosed after 12 months of age in those receiving two infant doses only highlights the importance of timely immunization, especially for the 12-month booster. This dose is critical not only for individual protection but also to maintain herd protection through reduction in carriage among toddlers.
Another contributing factor to vaccine failure was the single PCV dose from 12 months of age in the initial PCV7 catch-up campaign and among those who received PCV7-PCV7-PCV13, when the latter vaccine was introduced. Here, 2 PCV doses from 12 months of age doses might have reduced vaccine failure rates but would have involved additional vaccination and immunization visits during the catch-up campaign to prevent very few vaccine failure cases annually.
Comparison of PCV7 with PCV13 vaccine failure cases identified several important differences. Children with PCV13 failure were more likely to be healthy and develop LRTI. During 2006-2010 (after PCV7 introduction and before replacement with PCV13), we reported higher comorbidity prevalence among children with PCV7 failure compared with cases in unvaccinated children due to the same serotypes. Moreover, IPD due to the additional PCV13 serotypes was associated with lower comorbidity (17% vs 40%) and higher LRTI (58% vs 20%) prevalence compared to children with PCV7-type IPD [5] . This pattern was also observed for serotype 3 only, which is responsible for a third of vaccine failure cases in our PCV13 cohort. After PCV13 introduction, 19% of our PCV13 failure cases had comorbidity, compared to 9% among unvaccinated children with PCV13-type IPD prior to PCV13 introduction [5] . Any additional benefit of offering extra PCV13 doses to children with comorbidities (eg, using a 3 + 1 schedule) is likely to be negligible given the small numbers of PCV13 failures overall (23 cases) and in those with comorbidities (6 cases, including 5 in fully immunized children) in 2013-2014. Children with comorbidities are also benefiting from the continuing indirect (herd) protection offered by the current program. An important consideration for children with conjugate vaccine failure, especially those without known comorbidities, is the possibility of an undiagnosed underlying immune deficiency. In addition to clinical risk factors, immunoglobulin deficiency has been described in those with Hib [17] , but not MenC, vaccine failure [10] . In the United Kingdom, 11% of 172 children with IPD had transient IgG deficiency, which was only marginally below the lower limit for age [18] . We recently reported that, although a significant proportion of vaccinated children with vaccine-type IPD did not achieve protective antibody thresholds against the infecting serotype even after vaccination post-IPD, their IgG responses to the other vaccine serotypes remained intact, indicating that an underlying antibody deficiency was unlikely [19] . In a recent French study, however, 26 of 163 (16%) children with IPD had abnormal immunological investigations and 17 (10%) had a primary immunodeficiency, including MyD88 deficiency (n = 1), complement C2/C3 deficiency (n = 1), congenital asplenia (n = 1), and Bruton disease (X-linked agammaglobulinemia; n = 1) [20] . In addition to MyD88, a number of rare primary immunodeficiencies associated with mutations in Toll-like receptors, interleukin pathways (eg, IRAK4), and NEMO genes have been associated with (often recurrent) invasive bacterial infections in early childhood, mostly due to S. pneumoniae [21] . The extent of immunological investigations for individual children with conjugate vaccine failure is likely to require careful clinical assessment, taking into account the family and past history of serious infections as well as the severity of IPD. An underlying immune deficiency is more likely in children who develop IPD after 2 years of age [20] , and those with recurrent IPD [22] , but has not been reported for children with PCV failure, possibly because this is such a rare event.
In England and Wales, follow-up investigations in children with IPD were at the discretion of the attending clinician but, as the surveillance questionnaire was completed several weeks after the IPD episode, any immune deficiency identified after IPD would have been reported. It is also reassuring that second episodes and deaths among vaccine failure cases were rare.
This study has strengths and limitations. The established IPD surveillance spanning more than 2 decades alongside a national reference laboratory service has ensured high case ascertainment and near-complete follow-up of laboratory-confirmed cases. We did not include children diagnosed by urinary pneumococcal antigen or blood pneumococcal PCR; neither test is offered by local hospital laboratories or the national reference laboratory because nasopharyngeal carriage can give false-positive results in young children colonized with S. pneumoniae [23] . We also do not collect detailed information on IPD cases in children after their fifth birthday. If PCV13-type IPD cases do start appearing in older children because of waning immunity, for example, these would be identified through the ongoing national IPD surveillance. Finally, it was also not possible to compare vaccine failure rates between the 2 PCVs for several reasons, including noncontemporaneous introduction of the 2 vaccines, differences in circulating serotypes prior to vaccine introduction, differential serotype-specific carriage rates, invasiveness of individual serotypes, serotype-specific vaccine immunogenicity, and a catch-up program for PCV7 only. Each vaccine, however, has been used for approximately 4 years and these results suggest that vaccine failure is more common for the additional PCV13 serotypes, especially serotype 3.
CONCLUSIONS
Most children with PCV13 failure were healthy, developed LRTI, and survived their infection without long-term complications. The low prevalence of PCV7 failures after PCV13 introduction is reassuring and it is likely that PCV13 failures will also decline in the coming years. Given that most IPD cases are now due to non-PCV13 serotypes, there is an urgent need for serotype-independent subunit or whole-cell vaccines to control this devastating disease [24] .
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